Sanofi - Aventis Groupe: Press Release: Dupixent (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
Dupixent (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis Approval based on direct-to-Phase 3 program showing